


PRODUCT INFORMATION



MAB-CHMINACA-d₄ (exempt preparation)

Item No. 46411

CAS Registry No.: 2747913-91-1
Formal Name: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-d₄-3-carboxamide
Synonym: ADB-CHMINACA-d₄
MF: C₂₁H₂₆D₄N₄O₂
FW: 374.5
Chemical Purity: ≥98% (MAB-CHMINACA-d₄)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₄); ≤1% d₀
Supplied as: A 100 µg/ml solution in methanol
Storage: -20°C
Stability: ≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

MAB-CHMINACA-d₄ (exempt preparation) (Item No. 46411) is intended for use as an internal standard for the quantification of MAB-CHMINACA (Item Nos. 22047 | 16616) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

MAB-CHMINACA is categorized as a synthetic cannabinoid.^{1,2} It has been found in herbal blend products and has been involved in at least one case of fatal overdose.^{3,4} MAB-CHMINACA-d₄ is regulated as a Schedule I compound in the United States. MAB-CHMINACA-d₄ (exempt preparation) (Item No. 46411) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.

References

1. Buchler, I.P., Hayes, M.J., Hedge, S.G., *et al.* Indazole derivatives. *Pfizer Inc.* **WO2009/106982A1** (2009).
2. Carlier, J., Diao, X., Sempio, C., *et al.* Identification of new synthetic cannabinoid ADB-CHMINACA (MAB-CHMINACA) metabolites in human hepatocytes. *AAPS J.* **19(2)**, 568-577 (2017).
3. Hasegawa, K., Wurita, A., Minakata, K., *et al.* Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. *Forensic Toxicol.* **33(2)**, 380-387 (2015).
4. Adamowicz, P. and Gieroń, J. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA. *Clin. Toxicol. (Phila)* **54(8)**, 650-654 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/22/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM